“showed a trend”

The level of stress showed a trend towards a decrease in both groups between baseline and 12-month measurements (U = 602.5, p = 0.602) ( Table 2 ).

Compared with SBP 90-99 mm Hg patients, the risk of cardiovascular death in SBP 100-119 mm Hg group showed a trend of reduction (adjusted OR = 0.791, 95% CI 0.324-1.803, P = .602), and consistent findings were also observed for major adverse cardiac and cerebral events in the SBP 100-119 mm Hg group ( Table 3 ).

No significant difference in diagnostic yield was found among different family structures while cases that were sequenced as larger family structure showed a trend to be higher than those that were sequenced as singletons (33.7% vs 25.7; p = 0.602) ( Fig. 2 a).

Similarly, a retrospective cohort study of 296 cancer patients with VTE showed a trend toward lower mortality in the rivaroxaban group (8.0% vs. 10.0%, p = 0.602) ( Dong et al., 2024 ).

Compared with TPE, TCZ treatment showed a trend towards lower mortality rate (14-day mortality rate: 10.0% vs. 16.7%, p =0.608; 28-day mortality rate: 10.0% vs. 20.0%, p =0.480).

However, the CC rate at 36 months showed a trend in agreement with the previous results with a three-year incidence rate higher for irradiated breast implants (16.7% vs 7.6%, p = 0.608).

Patients with ER-negative tumors showed a trend toward poorer five-year survival than for those with ER-positive tumors, DFS was 56% vs. 83% (p = 0.609) and OS was 50% vs. 71% (p = 0.646), respectively.

Combining the data from 7 studies also showed a trend that high GPC3 expression was not associated with the tumor size ≥ 5 cm (OR: 1.08, 95% CI: 0.80–1.47, P = .61; Fig. 6 E).

Although no differences were found, the pessary group showed a trend towards a lower rate of perinatal adverse outcomes, being 11.1 % in the cerclage group and 3.7 % in the pessary group [RR: 0.33, 95 % CI: 0.04–3.01, p = 0.61] and NICU admission rates were lower [14.8 %] as compared to the cerclage group [38.5 %] [RR: 0.38, 95 % CI: 0.14–1.08, p = 0.066].

Left-handers showed a trend in the same positive direction, which did not approach significance, likely due to the small number of left-handers ( b = .022), F (1, 416) = 0.27, p = .61.

Sarcopenia alone at baseline showed a trend toward higher frailty odds (OR = 1.86, 95% CI: 0.17–20.51, p = 0.613), while interestingly osteopenia/osteoporosis alone showed a trend toward lower frailty odds (OR = 0.68, 95% CI: 0.15–3.21, p = 0.63).

Dark tadpoles showed a trend towards lower oxidative damage (MAD; t value = − 0.512, p-value = 0.62) and higher non-enzymatic antioxidant capacity (GSH/GSSG ratio; t value = 1.09, p-value = 0.301) compared to light tadpoles (Fig. 6 b,c).

Eye-contact ( M eye ( SD ) = 88.756 (47.616), M no_eye ( SD ) = 83.442 (40.116), F (1,41) eye_cont = 3.005, p = .091, η 2 p = 0.068, 95% CI [-0.859, 11.267]) showed a trend, and attribution ( M self ( SD ) = 84.913 (53.165), M other ( SD ) = 87.285 (37.378), F (1,41) attrib = 0.248, p = .621, η 2 p = 0.006, 95% CI [-12.691, 7.671]) did not have a significant main effect, indicating that participants attributed similar comfortable personal distance to the experimenter as to themselves (Fig 4a and 4b).

IFN-γ showed a trend of strong downregulation of >7-fold by both EV treatments ( p = 0.626).

Subgroup analysis on patients with either unchanged or up-staged disease showed a trend towards worse survival for patients with up-staged T stage ( P = 0.628; Supplementary Figure 1 ).

Conversely, patients with high estimated Ct values showed a trend toward an increased risk of major bleeding, with an incidence of 2.88 per 100 person-years compared with 1.15 in the within-range group (log-rank P = 0.64; HR and 95% CI 2.49 [0.31, 20.18], P = 0.39).

As for thigmotaxis, although not significant, 3×Tg-AD mice spent more time in the corners and along the walls compared to non-Tg mice (+21%, U = 18.5, n = 8 per group, p = 0.1719; Figure 1C ); likewise, statistical analysis of grooming behavior showed a trend toward an increase in 3×Tg-AD mice compared to non-Tg mice (+133%, U = 27, n = 8 per group, p = 0.6454; Figure 1D ).

Again, although the regression showed a trend in the hypothesized direction, it did not account for a significant amount of the variability ( r 2 (7) = 0.04, P = 0.65), indicating that S ECAP may not be a good predictor of S at the appropriate lower level, as discussed above.

Short mothers delivering LGA infants showed a trend towards relatively higher incidence of preeclampsia compared to those of average height with AGA (3.24% vs. 2.35%, P = 0.65).

The relatives of LFS carriers showed a trend toward lower physical well-being (men: 50.49 vs. 52.35; women 47.37 vs. 48.09, p = 0.65) but higher psychological well-being than LFS carriers (45.99 vs. 42.28, p = 0.07).

While combined methods showed a trend toward improvement (RR = 1.06, 95% CI: 0.98–1.15), this did not reach statistical significance (P = 0.657), with no heterogeneity (I2 = 0%).

In the low-dose group, the rate of disease progression showed a trend towards decrease after treatment (63% before vs. 43% at 12 months [ p = 0.659] vs. 44% at 24 months [ p = 0.637]) (Fig. 3b ).

Furthermore, senescent neurons co‐cultured with senescent microglia (B‐H group) showed a trend toward reduced apoptosis compared to senescent neurons alone (H 2 O 2 group): B‐H = 11.97% ± 1.198%, H 2 O 2 = 14.21% ± 2.544%, p = 0.66 (Figure 4f ).

As in univariate analysis, PCR negative patients, showed a trend towards higher all-cause mortality and readmission (HR 1.11, 95% CI 0.80–1.53, p < 0.66) ( Table 2 ), as well as increased all-cause mortality (HR 2.41, 95% CI 1.40–4.15, p < 0.01) as compared to patients without flu-like symptoms.

Neither serum PSA or ALP levels significantly differentiated patients based on OS, although ALP showed a trend towards significance (AUC= 0.55, p= 0.66; AUC= 0.73, p= 0.072, respectively) ( Figure 7A ).